Elena Nikulina

Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy

Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy
Camp4 unveils regRNA innovation

Camp4 Therapeutics Corp participated in the fourth annual BioConnect Investor Conference hosted by H.C. Wainwright & Co., where CEO Josh Mandel-Brehm joined a fireside chat to present the company’s regRNA-targeting platform aimed at increasing gene expression for treating diseases such as SYNGAP1.

The event, covered under the #regRNA and #GeneExpression themes, showcased Camp4 Therapeutics Corp’s latest research initiatives and efforts to translate RNA science into therapeutic breakthroughs for rare neurological disorders.

Earlier this year, Camp4 Therapeutics released a preprint outlining its expanded regRNA catalog using Capture-seq technology for gene expression research. The company also participated in a SYNGAP1 Symposium to engage with families and provide updates on its regRNA-based therapy progress. These initiatives reflect ongoing efforts to advance RNA-targeting treatments for rare neurological diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.